Introduction
============

Prostate cancer (PCa) is one of the most common cancers in males. Current guidelines (NCCN) consider radiation therapy (RT) as a therapeutic option in different disease stages using three-dimensional conformal RT (3D-CRT) and Intensity Modulated RT (IMRT) as the standard techniques ([@b1-mco-0-0-1855]).

The incidence of PCa is lower in developing than in western countries. However, a progressive increase in the incidence of PCa due to the prolonged life expectancy has been recorded ([@b2-mco-0-0-1855]). Furthermore, available RT technologies in developing countries have several limitations with several centres using only standard simulators and cobalt machines as the treatment planning and delivery technologies, respectively ([@b3-mco-0-0-1855]--[@b5-mco-0-0-1855]).

In the past, PCa irradiation was based on 2D techniques with treatment fields defined with standard simulators ([@b6-mco-0-0-1855],[@b7-mco-0-0-1855]). In the ′80s, further population-based indications for 2D-RT arose from the evaluation of prostate size and anatomical location using computed tomography (CT) scans ([@b8-mco-0-0-1855]). However, nowadays more detailed information and guidelines are available allowing tailored RT even with 2D technology.

In fact, RT of PCa is based on: i) clear guidelines on target definition related to risk categories ([@b9-mco-0-0-1855]); ii) treatment planning systems (TPS) to enable 3D dose evaluation with possibilities of computing a customized treatment plan for individual patients by adapting the beams geometry to different beam energies; iii) the possibility of defining standard irradiation geometries based on 3D dose distribution among a patients population.

Optimized 2D-RT based on these new insights could be helpful for centres without advanced RT technologies (3D-CRT, IMRT).

Based on this background, the purpose of this study was to propose practical guidelines for 2D-RT beams definition adapted to different PCa risk categories and different available beam energies.

Materials and methods
=====================

From our institution, 20 patients with histological confirmation of PCa, consecutively treated with RT were identified (median age: 72 years; range: 58--77 years; clinical T stage: cT2b: 3, cT2c: 5, cT3a: 9, cT3b: 3). Patients underwent CT-simulation in supine position after 3 days of laxatives to avoid rectal distension. Before CT-simulation commencement, 10 cc of contrast medium (Gastrografin) were injected into the rectum. Scans were performed every 5 mm from 3 cm below the ischial tuberosities to 3 cm above the promontory. Patients underwent pelvic MRI scan. MRI images were fused with CT-simulation images by using the VelocityAI system (Velocity Medical Solutions, Atlanta, GA) based on the B-spine algorithm for deformable registrations. In this way, delineation of the prostate and seminal vesicles was performed on MRI images. The delineated targets were then transferred to CT-simulation images for treatment planning.

Clinical Target Volume definition (CTV) was based on the EORTC guidelines ([@b9-mco-0-0-1855]). Irrespective of the individual patient\'s tumor stage, CTV delineation was done for four different categories: i) low-risk PCa: CTV = prostate; ii) intermediate-risk PCa: CTV = prostate + 5 mm radial margin, with inclusion of the caudal (1 cm) portion of the seminal vesicles; iii) high-risk PCa without involvement of the seminal vesicles: Prostate + 5 mm radial margin, with the inclusion of the caudal (2 cm) portion of the seminal vesicles; iv) high-risk PCa with involvement of seminal vesicles: prostate + 5 mm radial margin and inclusion of all the seminal vesicles. All contours were verified by an experienced operator and a senior consultant (GM, FD, AGM). Organs at Risk (OaRs) contours were defined according to the QUANTEC indications ([@b10-mco-0-0-1855]). The Planning Target Volume (PTV) was defined by adding a margin of 10 mm to the CTV in all directions ([@b11-mco-0-0-1855]).

For each patient, eight treatment plans were generated. For each of the four risk categories, two box technique treatment plans were calculated using a cobalt source or 10 MV photons. A fixed Source-Axis Distance (SAD) of 100 cm for Linear Accelerator and 80 cm for the cobalt unit was used. The beams weights were 20% (anterior-posterior and posterior-anterior beams) and 30% (lateral beams) to reduce the dose to the rectum, small bowel, and bladder. Beams were drawn using the standard collimators (without multileaf collimators). Standard collimators were initially placed at 5 mm distance with respect to the PTV margins. Then the minimum dose (defined as D98%) was evaluated. Fields sizes were gradually increased in steps of 5 mm to achieve the minimum PTV dose constraint (D98% \>95%). This progressive optimization was carried out with an iterative procedure, with several evaluations of cumulative dose/volume histograms and beams eye-view dose paintings. In this way, it was possible to identify the field sizes to be increased based on observed 'cold spots' sites.

Once the final plan was achieved, distances of the field edges from a set of reference points ([Tables I](#tI-mco-0-0-1855){ref-type="table"}--[IV](#tIV-mco-0-0-1855){ref-type="table"}) were measured. Both the maximum and the 95th percentile of the distances were identified. The latter value was taken as the 'recommended' value for radiation fields margin.

The study was approved by the institutional board High Technology Center for Research and Education-Ethical Committee (Campobasso, Italy) and it is registered in an international public registry ([ClinicalTrials.gov](ClinicalTrials.gov) Identifier: NCT03339531). Written informed consent was obtained from all of the enrolled patients for the use of their images in this study prior to the analysis.

Results
=======

[Tables I](#tI-mco-0-0-1855){ref-type="table"}--[IV](#tIV-mco-0-0-1855){ref-type="table"} show the results of the analysis in terms of fields margins from radiological landmarks margins in the various patient\'s categories: Low risk, intermediate risk, high risk, and high risk with involvement of seminal vesicles. Both the field margins needed to adequately irradiate all patients of the analysed sample and distances sufficient to achieve the same result in 95% of the enrolled patients are reported. The latter dimensions were defined as the 'recommended' margins. [Figs. 1](#f1-mco-0-0-1855){ref-type="fig"} and [2](#f2-mco-0-0-1855){ref-type="fig"} show the distances to be considered between fields margins and the radiological landmarks.

Discussion
==========

A planning study on real patients\' population was performed to suggest personalized treatment margins for 2D-RT. A box technique was used because it is easy to plan with a conventional simulator and dose conformity produced to the target. Furthermore, previous analysis showed that this technique produces planning results comparable to those achieved with more complex techniques (e.g., 6 beams) ([@b12-mco-0-0-1855]). Definition of anatomical structures like seminal vesicles and prostate apex location was performed with pelvic MRI co-registration. This integration was used based on the advantages of MRI in prostatic target definition as previously clearly demonstrated ([@b13-mco-0-0-1855]). Particularly, a study of Villeirs and colleagues showed that the fusion of MRI and CT in PCa contouring results in a moderate decrease of the CTV but a relevant decrease of inter-observer variation especially at the prostate apex ([@b14-mco-0-0-1855]).

Before CT-simulation, a small amount of contrast medium was injected into the rectum. This preparation although not required for CT-simulation was used to attain the same conditions for conventional simulation. In fact, the purpose of this study was to provide practical guidelines for this planning method. CTV to PTV margin of 10 mm was used based on a randomized trial which demonstrated that this margin produces the same clinical results compared to larger margins ([@b11-mco-0-0-1855]). This result was confirmed by Creak and colleagues who reported no evidence of a difference in PSA control according to CTV to PTV margin (1 cm vs. 1.5 cm) ([@b15-mco-0-0-1855]). It must be acknowledged that CTV to PTV margin lower than one centimetre is currently used. However, we considered this margin appropriate being that our suggestions are mostly addressed to centres without electronic portal imaging devices or more advanced image-guided technologies.

In this analysis, irradiation beams of different energies were simulated including beams produced by a cobalt machine. We must recognize that the use of cobalt machines is currently considered obsolete especially for PCa treatment. However, in many developing countries RT departments it is the only available treatment device ([@b3-mco-0-0-1855],[@b4-mco-0-0-1855]). The possibility of effective dose delivery with this type of treatment unit respecting the current dose/volume constraints remains uncertain. In particular, it is doubtful the possibility of an effective delivery to high tumor dose with safe OaRs irradiation using the box technique despite its practical advantages. It is generally believed that using only 4 beams, the delivery of \>60 Gy doses is impossible without reaching an excessive dosage to superficial tissues. In fact, PCa treatment with cobalt machines was often performed with rotational techniques. However, we still included in this analysis also irradiation with a cobalt machine due to the following reasons:

i\) Doses lower than the ones currently considered standard (\>70--75 Gy) (i) may still be useful in post-operative treatment; (ii) some randomized studies showed a significant biochemical and clinical benefit by delivering 60 Gy to the prostatic bed ([@b16-mco-0-0-1855]--[@b18-mco-0-0-1855]); ii) lower standard doses might still be effective if combined with androgen deprivation therapy (ADT); several randomized studies demonstrated a significant advantage in terms of specific or overall survival by combining ADT to RT at lower doses (65--70 Gy) than those currently considered as standards (\>70--75 Gy) ([@b19-mco-0-0-1855]--[@b23-mco-0-0-1855]);

iii\) the current recommended 'standard doses' were defined mainly based on biochemical relapse-free survival advantage and not in terms of overall survival ([@b11-mco-0-0-1855],[@b24-mco-0-0-1855]--[@b28-mco-0-0-1855]); the use of high doses in other words was less associated with a significant improvement of 'clinical' outcomes;

iv\) in addition, a meta-analysis including 7 randomized clinical trials compared the results achieved with conventional RT dose and high-dose RT. The latter resulted significantly associated with improved biochemical control but there was no difference in terms of mortality rate and specific prostate cancer mortality rate. Furthermore, a subgroup analysis showed that a dose of 64 Gy is associated with a 5-year biochemical relapse-free survival of 72, 61 and 40% in low, intermediate and high-risk PCa, respectively ([@b29-mco-0-0-1855]). Obviously, these results cannot be defined as optimal but may be acceptable in health systems where other alternative therapies or RT techniques are not available.

In our analysis we have not dealt with the problem of OaRs and planning organ at risk volumes. The main reason is that using a 2D-RT technique it is not possible to calculate the DVHs and to evaluate the constraints of OaRs including planning organ at risk volumes. However, the technique proposed by us is intended to be used with relatively low doses (60--64 Gy). In accordance to the QUANTEC, the maximum bladder dose should be less than 65 Gy and the V~65~ ~Gy~ of the rectum must be less than 25%, it is reasonably likely that these constraints are respected. Guidelines for PCa 2D-RT were obviously available in the past. However, these were mainly based on 'expert\'s opinion' or population-based CT measurements of prostate and seminal vesicles ([@b6-mco-0-0-1855],[@b8-mco-0-0-1855]). Our study presents obvious differences in terms of: i) precise MRI-based prostate and seminal vesicles contouring; ii) use of an additional margin between prostate and CTV according to risk category; iii) CTV to PTV margin validated by the results of a clinical trial ([@b11-mco-0-0-1855]); iv) definition of field margins adapted to different energy beams.

Probably in clinical practice it is possible to further optimize our instructions by customizing them to individual patients even with 2D technology. These optimizations can be implemented with simple diagnostic integrations feasible with a standard simulator.

Use of retrograde urethrography and cystography for example could enable an individualized location of the prostate apex and base, respectively ([@b30-mco-0-0-1855],[@b31-mco-0-0-1855]). In addition, it should be noted that the recommended margins in our study are based on the 95th percentile of the obtained measurement. This means that they may be considered adequate in 95% of patients. This choice derives from the need to obtain a compromise between tumor control probability and the risk of side effects. However, in the tables also the maximum value of the measured distance, i.e. the sizes appropriate in 100% of the evaluated sample was indicated. Therefore, in case of simulation images showing a reduced OaRs involvement, the planner can use the larger value to increase the likelihood of complete target 'coverage'. Although the limits of PCa irradiation with a cobalt machine have been previously mentioned, this analysis represents the basis for a subsequent study that has been planned in our center with the aim of defining the dose which can be safely administered with this kind of machine. The study will be conducted based on the current OaRs dose/volume constraints ([@b10-mco-0-0-1855]).

Our study was limited to prostate +/- seminal vesicles irradiation. However, according to current guidelines in high-risk patients, prophylactic irradiation of the pelvic lymph nodes is recommended ([@b1-mco-0-0-1855]). Therefore, a further study was planned to provide 2D indications for pelvic fields design based on current guidelines for nodal CTV definition ([@b32-mco-0-0-1855]). In conclusion, we aimed at providing convenient 2D PCa target delineation tools. In the last years, our team worked on the optimization of 2D-RT in palliative treatments ([@b33-mco-0-0-1855]--[@b35-mco-0-0-1855]). Worth noting is that 2D-RT is still in use in several centers in the world. Therefore, we think that other similar studies based on advanced radiological technologies could be performed to optimize 2D-RT techniques in other tumors for less equipped departments.
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![Position and direction of the margins indicated in the tables (on the anterior field). 'A' indicates the distance between the lateral field margin and the center of the symphysis pubis; 'B' indicates the distance between the inferior margin of the field and the bottom of ischial tuberosities; and 'C' indicates the distance between the superior field margin and the top of the symphysis pubis.](mco-11-01-0037-g00){#f1-mco-0-0-1855}

![Position and direction of the margins indicated in the tables (on the lateral fields). RE, rectum; SP, symphysis pubis; 'D', distance between the anterior field margin and the posterior margin of the symphysis pubis; 'E', the distance between posterior field margin and the most anterior point of the rectal wall.](mco-11-01-0037-g01){#f2-mco-0-0-1855}

###### 

Field definition: Low risk prostate cancer.

                                                                                                          Treatment machine   
  -------------------- ----------- ---------------------------------------------------------------------- ------------------- -----------
  Anterior-posterior   Lateral     From the center of the symphisis pubis (laterally) \[A\]               5.7 (5.7)           4.5 (5.0)
                       Inferior    From the bottom of ischial tuberosities (above) \[B\]                  0.9 (0.9)           1.4 (1.8)
                       Superior    From the top of the symphisis pubis (above) \[C\]                      5.4 (6.7)           4.9 (5.7)
  Lateral              Anterior    From the posterior margin of the symphisis pubis (posteriorly) \[D\]   0.3 (0.4)           0.4 (0.5)
                       Posterior   From the most anterior point of the rectum (posteriorly) \[E\]         4.7 (5.9)           3.3 (3.7)
                       Inferior    From the bottom of ischial tuberosities (above)                        0.9 (0.9)           1.4 (1.8)
                       Superior    From the top of the symphisis pubis (above)                            5.4 (6.7)           4.9 (5.7)

Reported measures represent the minimal individual field margins needed to respect the constraint D98 (minimal dose) \>95%. Measures are expressed in cm. Indicated measures (those not in brackets) represent the 95th percentile of the measured distances (recommended margins). The values presented in round brackets indicate the maximum measured distances. The letters presented in square brackets correspond to the letter indicators in [Figs. 1](#f1-mco-0-0-1855){ref-type="fig"} and [2](#f2-mco-0-0-1855){ref-type="fig"}.

###### 

Field definition: Intermediate risk prostate cancer.

                                                                                                          Treatment machine   
  -------------------- ----------- ---------------------------------------------------------------------- ------------------- -----------
  Anterior-posterior   Lateral     From the center of the symphisis pubis (laterally) \[A\]               6.2 (6.8)           5.2 (5.5)
                       Inferior    From the bottom of ischial tuberosities (above) \[B\]                  0.5 (1.0)           1.3 (1.4)
                       Superior    From the top of the symphisis pubis (above) \[C\]                      5.5 (7.9)           5.0 (6.3)
  Lateral              Anterior    From the posterior margin of the symphisis pubis (posteriorly) \[D\]   0.3 (0.4)           0.3 (0.4)
                       Posterior   From the most anterior point of the rectum (posteriorly) \[E\]         4.9 (6.0)           3.8 (4.2)
                       Inferior    From the bottom of ischial tuberosities (above)                        0.5 (1.0)           1.3 (1.4)
                       Superior    From the top of the symphisis pubis (above)                            5.5 (7.9)           5.0 (6.3)

Reported measures represent the minimal individual field margins needed to respect the constraint D98 (minimal dose) \>95%. Measures are expressed in cm. Indicated measures (those not in brackets) represent the 95th percentile of the measured distances (recommended margins). The values presented in round brackets indicate the maximum measured distances. The letters presented in square brackets correspond to the letter indicators in [Figs. 1](#f1-mco-0-0-1855){ref-type="fig"} and [2](#f2-mco-0-0-1855){ref-type="fig"}.

###### 

Field definition: High-risk prostate cancer.

                                                                                                          Treatment machine   
  -------------------- ----------- ---------------------------------------------------------------------- ------------------- -----------
  Anterior-posterior   Lateral     From the center of the symphisis pubis (laterally) \[A\]               7.1 (9.0)           5.7 (5.8)
                       Inferior    From the bottom of ischial tuberosities (above) \[B\]                  0.4 (0.8)           1.3 (1.3)
                       Superior    From the top of the symphisis pubis (above) \[C\]                      7.6 (9.3)           5.1 (6.9)
  Lateral              Anterior    From the posterior margin of the symphisis pubis (posteriorly) \[D\]   0.3 (0.3)           0.3 (0.4)
                       Posterior   From the most anterior point of the rectum (posteriorly) \[E\]         6.2 (8.0)           4.4 (4.8)
                       Inferior    From the bottom of ischial tuberosities (above)                        0.4 (0.8)           1.3 (1.3)
                       Superior    From the top of the symphisis pubis (above)                            7.6 (9.3)           5.1 (6.9)

Reported measures represent the minimal individual field margins needed to respect the constraint D98 (minimal dose) \>95%. Measures are expressed in cm. Indicated measures (those not in brackets) represent the 95th percentile of the measured distances (recommended margins). The values presented in round brackets indicate the maximum measured distances. The letters presented in square brackets correspond to the letter indicators in [Figs. 1](#f1-mco-0-0-1855){ref-type="fig"} and [2](#f2-mco-0-0-1855){ref-type="fig"}.

###### 

Field definition: High-risk prostate cancer with seminal vesicle involvement.

                                                                                                          Treatment machine   
  -------------------- ----------- ---------------------------------------------------------------------- ------------------- -----------
  Anterior-posterior   Lateral     From the center of the symphisis pubis (laterally) \[A\]               7.7 (9.8)           6.7 (6.9)
                       Inferior    From the bottom of ischial tuberosities (above) \[B\]                  0.4 (0.6)           1.0 (1.3)
                       Superior    From the top of the symphisis pubis (above) \[C\]                      8.7 (9.1)           6.6 (7.3)
  Lateral              Anterior    From the posterior margin of the symphisis pubis (posteriorly) \[D\]   0.3 (0.4)           0.3 (0.4)
                       Posterior   From the most anterior point of the rectum (posteriorly) \[E\]         6.7 (8.1)           5.1 (6.0)
                       Inferior    From the bottom of ischial tuberosities (above)                        0.4 (0.6)           1.0 (1.3)
                       Superior    From the top of the symphisis pubis (above)                            8.7 (9.1)           6.6 (7.3)

Reported measures represent the minimal individual field margins needed to respect the constraint D98 (minimal dose) \>95%. Measures are expressed in cm. Indicated measures (those not in brackets) represent the 95th percentile of the measured distances (recommended margins). The values presented in round brackets indicate the maximum measured distances. The letters presented in square brackets correspond to the letter indicators in [Figs. 1](#f1-mco-0-0-1855){ref-type="fig"} and [2](#f2-mco-0-0-1855){ref-type="fig"}.
